Lesch-Nyhan syndrome is a rare hereditary disease characterized by severe neurological disorders and hyperuricemia. The pathology is caused by a deficiency of the enzyme hypoxanthine-guanine-phosphoribosyltransferase (HGPRT), which leads to a violation of purine metabolism and the accumulation of uric acid in the body. The clinical picture includes a combination of symptoms: self-injurious behavior, mental retardation, spastic quadriparesia and gouty arthritis. The first signs of the disease usually appear at the age of 3-6 months with the development of hypotonia, which later transforms into spasticity. The disease is extremely severe and requires a comprehensive approach to diagnosis and treatment.
History of the disease and interesting historical facts
The disease was first described in 1964 by American doctors Michael Lesch and William Nyhan. The researchers presented a clinical case of two brothers suffering from an unusual combination of symptoms, including mental retardation, cerebral palsy and gout. Interestingly, this observation became the starting point for understanding metabolic disorders of purine metabolism. “The discovery of Lesch-Nyhan syndrome was an important step in the development of medical genetics,” notes Dr. James Watson, a Nobel Prize laureate in physiology or medicine. In the following years, the biochemical basis of the disease was established and diagnostic methods were developed.
Epidemiology
Lesch-Nyhan syndrome occurs with a frequency of approximately 1 case per 380,000 male births. The disease has an X-linked recessive type of inheritance, so it almost always affects boys. According to the international registry of rare diseases, the average life expectancy of patients is 20-40 years, although there are cases of reaching the age of 60 years with adequate treatment. Mortality is highest in the first two decades of life, mainly due to renal failure and infectious complications. The prevalence of the disease does not have significant geographic or ethnic differences.
Genetic predisposition to this disease
The cause of the disease is mutations in the HPRT1 gene, located in the Xq26-q27.2 region of chromosome X. This gene encodes the hypoxanthine-guanine phosphoribosyltransferase enzyme, which plays a key role in the salvage pathway of purine metabolism. More than 400 different mutations of this gene have been identified, including missense mutations, nonsense mutations, deletions, and splicing mutations. The severity of the enzyme deficiency correlates with the severity of clinical manifestations. The table below demonstrates the relationship between the type of mutation and the clinical picture:
| Type of mutation | HGPRT (%) activity level | Clinical picture |
|---|---|---|
| Null mutations | 0% | Classic Lesch-Nyhan syndrome |
| Missense mutations | 1-8% | Lesha-Nihan variants |
| Splicing mutations | Variable | Mixed forms |
Risk factors for the development of this disease
The main risk factor is the presence of a mutation in the HPRT1 gene in the mother, who is a carrier of the pathological allele. Other significant factors are:
- Consanguineous marriages in the family
- High age of parents at conception
- Exposure to mutagenic factors during pregnancy
- Living in ecologically unfavorable regions
Chemical mutagens such as benzene and its derivatives are particularly dangerous, as they can cause mutations in germ cells. The risk of developing the disease increases significantly if there is a family history of X-linked pathologies.
Diagnosis of this disease
Clinical diagnosis is based on a characteristic triad of symptoms:
- Hyperuricemia and its consequences
- Neurological disorders
- Mental disorders
Laboratory diagnostics include determination of uric acid levels in blood and urine, which are significantly elevated (>20 mg/dl). To confirm the diagnosis, a study of the activity of the HGPRT enzyme in red blood cells is performed. Genetic testing can identify a specific mutation in the HPRT1 gene. Radiological examination shows the presence of urate stones in the kidneys and urinary tract. Differential diagnosis is carried out with other causes of hyperuricemia and neurological diseases of childhood.
Treatment
Therapy is aimed at correcting metabolic disorders and controlling neurological symptoms. General treatment includes:
- A strict diet with limited purines
- Drink plenty of fluids to prevent urate nephrolithiasis
- Physiotherapy and rehabilitation measures
Pharmacological treatment is based on the use of allopurinol to reduce uric acid production. If necessary, lithotripsy or surgical removal of urate stones is performed. Neuroleptics and benzodiazepines are used to control self-injurious behavior. Other treatments include psychotherapy and special education.
List of drugs used to treat this disease
- Allopurinol (initial dose 100-300 mg/day)
- Rasbutyrine (alternative to allopurinol)
- Haloperidol (to control aggression)
- Diazepam (for severe spasticity)
- Uricosuric drugs (if needed)
- Anticonvulsants (as indicated)
Dosage selection is carried out individually, taking into account the severity of the patient's condition and the presence of complications.
Disease monitoring
Regular monitoring includes the following steps:
- Every 3 months: check uric acid levels
- Every six months: ultrasound of the kidneys and urinary tract
- Annually: neurological assessment
- As needed: consultations with a psychiatrist and psychologist
The prognosis depends on the timeliness of diagnosis and the quality of therapy. The main complications are: renal failure, recurrent gouty arthritis, disability due to neurological disorders.
Age-related features of the disease
Clinical manifestations vary significantly depending on the patient's age:
- 0-6 months: hypotonia, psychomotor developmental delay
- 6-12 months: development of spasticity, onset of self-injurious behavior
- 1-5 years: maximum severity of neurological symptoms
- School age: stabilization of the condition with adequate therapy
- Adulthood: Social adaptation is possible with early treatment
Each age period requires special approaches to rehabilitation and supportive therapy.
Questions and Answers
- How can you prevent a child from being born with Lesch-Nyhan syndrome? Conducting genetic counseling and prenatal diagnostics in families with a burdened medical history allows us to determine the risk of having a sick child.
- Is it possible to completely cure this disease? A complete cure is impossible, but modern treatment methods can significantly improve the quality of life of patients.
- How long do patients with this diagnosis live? With adequate treatment, the average life expectancy is 20-40 years, but there are cases of reaching the age of 60 years.
- What to do if a child shows signs of illness? It is necessary to immediately contact a geneticist for diagnosis and treatment.
- Is the disease hereditary? Yes, the syndrome is inherited in an X-linked recessive manner, so boys are more often affected.
Advice from Dr. Oleg Korzhikov
“Many parents often ask me about how to properly help a child with Lesch-Nyhan syndrome. Here are some important recommendations:
- Monitor your uric acid levels regularly and do not miss doses of allopurinol.
- Ensure sufficient drinking regime - at least 2-3 liters of liquid per day
- Start rehabilitation measures in a timely manner, they are critical to prevent contractures
- Don't ignore the help of a psychiatrist - proper drug-based behavioral correction significantly improves the quality of life
- Remember that early treatment has a significant impact on the prognosis of the disease.
The main thing is not to give up and remember that even with such a serious diagnosis, it is possible to achieve good results with a comprehensive approach to treatment.”
